# Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder

> **NCT03017508** · PHASE2,PHASE3 · COMPLETED · sponsor: **Yale University** · enrollment: 22 (actual)

## Conditions studied

- Social Anxiety Disorder
- Performance Anxiety

## Interventions

- **DRUG:** BHV-0223
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03017508
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2019-12
- **Final completion:** 2021-01-29
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2021-05-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03017508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03017508, "Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03017508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*